| P50 | author | Vinod Kumar Vashistha | Q89915459 |
| P2093 | author name string | Anuj Kumar | |
| P2860 | cites work | Pharmacodynamic and pharmacokinetic studies on bufuralol in man | Q24540333 |
| | The α- and β-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers | Q24679972 |
| | Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs | Q28259340 |
| | Characterization of [3H](+/-)carazolol binding to beta-adrenergic receptors. Application to study of beta-adrenergic receptor subtypes in canine ventricular myocardium and lung | Q28260291 |
| | Labetalol: A Review of Its Pharmacology, Pharmacokinetics, Clinical Uses and Adverse Effects | Q28265575 |
| | Suppression of premature ventricular contractions by acebutolol | Q28318059 |
| | Pharmacological properties of diacetolol (M&B 16,942), a major metabolite of acebutolol | Q29544857 |
| | Recent advances in structure, binding sites with ligands and pharmacological function of beta-adrenoceptors obtained by molecular biology and molecular modeling | Q33967935 |
| | Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology | Q34054672 |
| | Stereoselectivity and affinity in molecular pharmacology. III. Structural aspects in the mode of action of natural and synthetic auxins | Q34261730 |
| | Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers—N‐desisopropylation is mediated mainly by CYP1A2 | Q34347501 |
| | Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. | Q34387461 |
| | Recent antiarrhythmic drugs | Q34514439 |
| | Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs | Q34560259 |
| | Stereoselective renal clearance of pindolol in humans | Q34563398 |
| | Esmolol inhibits Na+ current in rat ventricular myocytes | Q34603792 |
| | Racemic therapeutics--ethical and regulatory aspects | Q34618855 |
| | Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure | Q74141094 |
| | Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity | Q80066228 |
| | Vasodilatory mechanism of levobunolol on vascular smooth muscle cells | Q80217247 |
| | Methods and approaches for determination and enantioseparation of (RS)-propranolol | Q91022756 |
| | Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs | Q34725737 |
| | Stereoselective features of (R)- and (S)-atenolol: clinical pharmacological, pharmacokinetic, and radioligand binding studies | Q34729739 |
| | Putting chirality to work: the strategy of chiral switches | Q34932119 |
| | Effects of (plus or minus)-propranolol, (plus or minus)-,(plus)-, and (minus)-alprenolol on unanaesthetized dogs with ventricular arrhythmias resulting from coronary artery ligation | Q35225970 |
| | Clinical Pharmacokinetics of β-Adrenoreceptor Blocking Drugs | Q35373296 |
| | Chirality. Clinical pharmacokinetic and pharmacodynamic considerations | Q37920866 |
| | Pharmacology, pharmacodynamics and pharmacokinetics of sotalol | Q38137732 |
| | Stereoselective delivery and actions of beta receptor antagonists | Q39465781 |
| | Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy | Q39465857 |
| | Pharmacodynamic, Pharmacokinetic and Antiarrhythmic Properties of d-Sotalol, the Dextro-Isomer of Sotalol | Q40438889 |
| | Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol. | Q40620240 |
| | The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias | Q41357289 |
| | The impact of stereoisomerism in bioequivalence studies | Q41926132 |
| | A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects | Q42676120 |
| | Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol | Q43690830 |
| | Pharmacokinetics of nebivolol in the rat: low oral absorption, loss in the gut and systemic stereoselectivity | Q43857564 |
| | Influence of input rate on the stereospecific and nonstereospecific first pass metabolism and pharmacokinetics of metoprolol extended release formulations | Q43968167 |
| | Effect of aging on the pharmacokinetics of acebutolol enantiomers. | Q44150588 |
| | Stereoselective metabolism of metoprolol: enantioselectivity of alpha-hydroxymetoprolol in plasma and urine | Q44458311 |
| | Antioxidant activity of nebivolol in the rat aorta | Q44688483 |
| | The pharmacokinetics of the enantiomers of atenolol | Q46096913 |
| | The rate of onset of beta adrenergic blockade by the optical isomers of alprenolol | Q46174948 |
| | Stereoselective analysis of labetalol in human plasma by LC-MS/MS: application to pharmacokinetics | Q46249315 |
| | Involvement of nitric oxide in both central and peripheral haemodynamic effect of D/L-nebivolol and its enantiomers in rats. | Q46406081 |
| | Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate | Q46546572 |
| | Stereoselective analysis of metoprolol and its metabolites in rat plasma with application to oxidative metabolism. | Q46609045 |
| | Stereoisomers of compounds with symmetric constitutions | Q46799149 |
| | Bioassay, determination and separation of enantiomers of atenolol by direct and indirect approaches using liquid chromatography: A review. | Q48348991 |
| | Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties. | Q55065711 |
| | Pharmacokinetics and Metabolism of Bisoprolol Enantiomers in Humans | Q56620130 |
| | Optical Isomers of Propranolol | Q59085467 |
| | FDA's policy statement for the development of new stereoisomeric drugs | Q67519987 |
| | Stereoselective accumulation of the ?-receptor blocking drug atenolol by human platelets | Q67886312 |
| | Pharmacological characteristics of the stereoisomers of carvedilol | Q68093321 |
| | Enantioselective and diastereoselective hydroxylation of bufuralol. Absolute configuration of the 7-(1-hydroxyethyl)-2-[1-hydroxy-2-(tert-butylamino)ethyl]benzofurans, the benzylic hydroxylation metabolites | Q68318821 |
| | Beta-adrenergic blocking agents. 3. The optical isomers of pronethalol, propranolol, and several related compounds | Q68729783 |
| | Beta-adrenoceptor antagonist activities and binding affinities of timolol enantiomers in rat atria | Q69376447 |
| | Interaction of bisoprolol with cimetidine and rifampicin | Q69890125 |
| | Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics | Q69990647 |
| | Protein binding of sotalol enantiomers in young and elderly human and rat serum using ultrafiltration | Q70930475 |
| | Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite | Q71033416 |
| | Stereoselective disposition of carvedilol is determined by CYP2D6 | Q72281181 |
| | Stereoselective pharmacokinetics of bisoprolol after intravenous and oral administration in beagle dogs | Q73327737 |
| | Differential tissue distribution of the enantiomers of racemic pindolol in the rat | Q73384138 |
| | Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs | Q73895463 |
| P577 | publication date | 2020-02-27 | |
| P1433 | published in | Chirality | Q2120255 |
| P1476 | title | Stereochemical facets of clinical β-blockers: An overview | |